Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

ClinicalTrials.gov ID: NCT00272038

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00272038. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study Investigating the Efficacy and Activity of Single Agent Erlotinib in Chemotherapy-Naive Androgen Independent Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Objectives to evaluate the activity of Erlotinib in prostate cancer patients who are hormone refractory and androgen independent and have not been exposed to chemotherapy.

Study identification

NCT ID: NCT00272038
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Oncology Specialists, S.C.; Other
Enrollment: 29 participants

Conditions and interventions

Conditions

Prostate Cancer

Interventions

Tarceva Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: Male
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2005 (Type not available)
Primary completion: Oct 2010 (Actual)
Completion: Oct 2010 (Actual)
Last update posted: Jun 27, 2018

2005 – 2010

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Oncology Specialists, SC	Park Ridge	Illinois	60068	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00272038, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 27, 2018 · Synced Nov 13, 2026